Materialise Glenius

Materialise Glenius is a personalized implant for treating non-inflammatory and inflammatory degenerative joint disease, bone deformities at the glenoid, and structural bone loss of the scapula. Most patients present Wallace type 2 and 3 defects in primary and revision cases. 

Currently, Materialise Glenius is sold directly in Australia and Europe — Austria, Belgium, Denmark,  Germany, the Netherlands, Norway, Portugal, Sweden, Switzerland, and the United Kingdom. It is not yet commercially available in Canada and the US.  

Reimbursement differs per country and is dependent on legislation or on hospitals' contracts with insurance companies, DRG systems, or special funds.  

If you would like to know the specific reimbursement possibilities applicable to your country, please contact us at medical@materialise.com for more details.   

Image data is uploaded directly to the patient case via Materialise SurgiCase. Image upload can be done by a surgeon, radiologist, or other staff. Please refer to the SurgiCase User Guide for ‘Image Upload’ instructions in the ‘Help’ menu in the SurgiCase platform for more information. If you still don’t have a SurgiCase account, please contact your regional account manager or medical@materialise.be 

You can expect our 3D analysis and implant proposal within seven working days from the upload of acceptable images according to the Materialise Scan Protocol Shoulder. The timing is dependent on your availability to provide feedback on the surgical plan. Once we receive approval on the final implant, the implant will be produced and delivered in 5 to 6 weeks.  

It is advised to use the guides, implant, and models within six months of performing the CT scans on which they are based. If the patient’s anatomy has changed significantly since the time of the CT scan, the guides, models, and implant should not be used, even if the time period of six months has not expired.